A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 65M | 60M | 0 |
| Net Income | -7.2M | -7.2M | -8.4M | 14M | 11M | -2.7M |
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | -5.3M | -5.3M | -7.8M | -3.9M | 2.2M | -2.5M |
| ROIC | 575.4% | 144.6% | 123.0% | 16.1% | 20.6% | -63.8% |
| Gross Margin | - | - | - | 43.7% | 46.7% | - |
| Debt/Equity | 0.00 | 2.45 | 0.92 | 0.29 | 0.17 | 0.01 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | 6.9M | 6.9M | 8.1M | 14M | 15M | -2.8M |
| Operating Margin | 0.0% | - | - | 21.0% | 25.0% | - |
| ROE | -626.1% | -626.1% | -237.4% | 23.9% | 19.3% | -239.2% |
| Shares Outstanding | 0M | 0M | 0M | 0M | 0M | 0M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 60M | 65M | 0 | 0 | 0 |
| Gross Margin | N/A | 46.7% | 43.7% | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -2.8M | 15M | 14M | 8.1M | 6.9M | 6.9M |
| Op. Margin | N/A | 25.0% | 21.0% | N/A | N/A | 0.0% |
| Net Income | -2.7M | 11M | 14M | -8.4M | -7.2M | -7.2M |
| Net Margin | N/A | 18.9% | 21.6% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -63.8% | 20.6% | 16.1% | 123.0% | 144.6% | N/M |
| ROE | -239.2% | 19.3% | 23.9% | -237.4% | -626.1% | -626.1% |
| ROA | -78.6% | 10.1% | 11.5% | -109.6% | -133.4% | -133.4% |
| Cash Flow | ||||||
| Op. Cash Flow | -2.3M | 8.2M | 3.1M | -7.6M | -5.3M | -5.3M |
| Free Cash Flow | -2.5M | 2.2M | -3.9M | -7.8M | -5.3M | -5.3M |
| Owner Earnings | -2.9M | 3.4M | -1.0M | -8.7M | -6.6M | -6.6M |
| CapEx | 223K | 6.0M | 7.0M | 146K | 17K | 17K |
| Maint. CapEx | 138K | 3.3M | 4.1M | 806K | 818K | 818K |
| Growth CapEx | 85K | 2.7M | 2.9M | 0 | 0 | 0 |
| D&A | 138K | 3.3M | 4.1M | 806K | 818K | 818K |
| CapEx/OCF | N/A | 73.5% | 223.9% | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 6.6M | 4.7M | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 1.2M | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 468K | 1.5M | 73K | 303K | 440K | 440K |
| Debt Repayment | 0 | 16M | 18M | 797K | 812K | 812K |
| Balance Sheet | ||||||
| Net Debt | -2.3M | 2.3M | 12M | 1.7M | 2.6M | -204K |
| Cash & Equiv. | 2.3M | 7.7M | 5.0M | 1.6M | 204K | 204K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.01 | 0.17 | 0.29 | 0.92 | 2.45 | 0.00 |
| Interest Coverage | -64.7 | 8.9 | 6.0 | 20.5 | 19.8 | 19.8 |
| Equity | 1.1M | 58M | 59M | 3.5M | 1.1M | 1.1M |
| Total Assets | 3.4M | 112M | 122M | 7.6M | 5.4M | 5.4M |
| Total Liabilities | 2.3M | 49M | 56M | 4.1M | 4.3M | 4.3M |
| Intangibles | 0 | 3.4M | 3.7M | 587K | 611K | 611K |
| Retained Earnings | -10M | 34M | 40M | -30M | -38M | -38M |
| Working Capital | 178K | 9.7M | 4.6M | 1.8M | -409K | -409K |
| Current Assets | 2.5M | 49M | 43M | 2.7M | 1.1M | 1.1M |
| Current Liabilities | 2.3M | 39M | 39M | 926K | 1.5M | 1.5M |
| Per Share Data | ||||||
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Owner EPS | N/A | N/A | N/A | N/A | N/A | N/A |
| Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | 0.2 | 0.9 | 0.2 | 0.4 | -0.0 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 0 |
| Avg. Price | 6.20 | 3.63 | 1.24 | 1.78 | 1.43 | 9.76 |
| Year-End Price | 8.90 | 1.36 | 1.08 | 2.05 | 0.82 | 9.76 |
HEMOGENYX PHARMACEUTICALS PLC O passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 48.1% with a gross margin of 45.2%.
HEMOGENYX PHARMACEUTICALS PLC O (HEMO-L) has a 5-year average return on invested capital (ROIC) of 48.1%. This indicates strong capital allocation and a potential competitive advantage.
HEMOGENYX PHARMACEUTICALS PLC O (HEMO-L) does not currently pay a regular dividend.
HEMOGENYX PHARMACEUTICALS PLC O (HEMO-L) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
HEMOGENYX PHARMACEUTICALS PLC O (HEMO-L) has a debt-to-equity ratio of 2.45. This indicates higher leverage, which may increase financial risk.
HEMOGENYX PHARMACEUTICALS PLC O (HEMO-L) has a return on equity (ROE) of -626.1%. A negative ROE may indicate losses or negative equity.
HEMOGENYX PHARMACEUTICALS PLC O (HEMO-L) has a 5-year average gross margin of 45.2%. This indicates decent pricing power.
The Ledger Terminal provides 5 years of financial data for HEMOGENYX PHARMACEUTICALS PLC O (HEMO-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.